title: Targeting receptor tyrosine kinases in solid tumors.
abstract: Tyrosine kinase (TK) cascades are involved in all stages of tumorigenesis through modulation of transformation and differentiation, cell-cycle progression, and motility. Advances in molecular targeted drug development allow the design and synthesis of inhibitors targeting cancer-associated signal transduction pathways. Potent selective inhibitors with low toxicity can benefit patients with local and metastatic malignancies. This article evaluates information on solid tumor-related TK signaling and inhibitors, including receptor TK signal pathways that lead to successful application in clinical settings, properties of recently approved TK-inhibitor drugs for the treatment of solid tumors, and potential TK pathways for future therapeutic interventions.
authors.affiliation: Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
authors.forename: Jianliang
authors.initials: J
authors.lastname: Zhang
authors.forename: Steven N
authors.initials: SN
authors.lastname: Hochwald
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases
keywords: Cancer; Solid tumors; Tyrosine kinase inhibitors